STXBP1 Gene Therapy Viral Vector Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapeutic approaches fail to effectively address the underlying disease mechanism of STXBP1 genetic disorders, such as Ohtahara syndrome, West syndrome, and Dravet syndrome, which are characterized by loss of syntaxin binding protein 1 (STXBP1) functional activity, leading to severe neurodevelopmental and epileptic symptoms.
Innovation Solution
A gene therapy approach that overexpresses a healthy copy of the STXBP1 gene using a nucleic acid construct and viral vector to restore normal STXBP1 functional activity, administered via viral particles to compensate for mutation effects and treat or prevent STXBP1-related disorders.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current therapeutic approaches are used, then treatment is provided, but the underlying disease mechanism of STXBP1 genetic disorders is not effectively addressed
Solution Approach 1:
A viral vector is used as an intermediary delivery system to introduce a functional copy of the STXBP1 gene into patient cells. The viral vector acts as a mediator between the therapeutic gene and the target cells, enabling effective delivery and expression of the corrective gene product to address the underlying disease mechanism.
Solution Approach 2:
A functional copy of the STXBP1 gene is introduced into cells carrying loss-of-function mutations. This copied gene serves as a replacement for the defective endogenous gene, restoring normal protein function and addressing the root cause of the disorder through gene supplementation.
2Reliability
If gene therapy is administered via viral particles, then STXBP1 functional activity is restored, but delivery efficiency and targeting precision must be optimized
Solution Approach 1:
The viral vector system parameters are optimized including selecting appropriate viral serotypes, adjusting viral titers, and modifying vector design elements to enhance delivery efficiency and targeting precision while maintaining safety and immunogenicity profiles.
Data Source
AI summary
The present invention relates to a nucleic acid construct comprising a transgene encoding syntaxin binding protein 1 (STXBP1, Munc-18), a viral vector for packaging said nucleic acid in a viral particle; and use of such viral particle for treating disease associated with a loss of STXBP1 functional activity.